208 related articles for article (PubMed ID: 37407956)
1. Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction - a post-hoc analysis of the EMMY trial.
Benedikt M; Mangge H; Aziz F; Curcic P; Pailer S; Herrmann M; Kolesnik E; Tripolt NJ; Pferschy PN; Wallner M; Zirlik A; Sourij H; von Lewinski D
Cardiovasc Diabetol; 2023 Jul; 22(1):166. PubMed ID: 37407956
[TBL] [Abstract][Full Text] [Related]
2. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
Tripolt NJ; Kolesnik E; Pferschy PN; Verheyen N; Ablasser K; Sailer S; Alber H; Berger R; Kaulfersch C; Leitner K; Lichtenauer M; Mader A; Moertl D; Oulhaj A; Reiter C; Rieder T; Saely CH; Siller-Matula J; Weidinger F; Zechner PM; von Lewinski D; Sourij H;
Am Heart J; 2020 Mar; 221():39-47. PubMed ID: 31901799
[TBL] [Abstract][Full Text] [Related]
3. Ketone body levels and its associations with cardiac markers following an acute myocardial infarction: a post hoc analysis of the EMMY trial.
Aziz F; Tripolt NJ; Pferschy PN; Scharnagl H; Abdellatif M; Oulhaj A; Benedikt M; Kolesnik E; von Lewinski D; Sourij H
Cardiovasc Diabetol; 2024 Apr; 23(1):145. PubMed ID: 38678253
[TBL] [Abstract][Full Text] [Related]
4. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
[TBL] [Abstract][Full Text] [Related]
5. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.
Paolisso P; Bergamaschi L; Santulli G; Gallinoro E; Cesaro A; Gragnano F; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Casella G; Mauro C; Vassilev D; Marfella R; Calabrò P; Barbato E; Pizzi C
Cardiovasc Diabetol; 2022 May; 21(1):77. PubMed ID: 35570280
[TBL] [Abstract][Full Text] [Related]
6. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
[TBL] [Abstract][Full Text] [Related]
7. Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial.
Sourij C; Aziz F; Tripolt NJ; Siller-Matula J; Pferschy PN; Kolesnik E; Wallner M; Eyileten C; Postula M; Oulhaj A; Sourij H; von Lewinski D;
Hellenic J Cardiol; 2024; 75():3-8. PubMed ID: 37236318
[TBL] [Abstract][Full Text] [Related]
8. The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).
Omar M; Jensen J; Kistorp C; Højlund K; Videbæk L; Tuxen C; Larsen JH; Andersen CF; Gustafsson F; Køber L; Schou M; Møller JE
Cardiovasc Diabetol; 2022 Feb; 21(1):34. PubMed ID: 35219331
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin in acute myocardial infarction: the EMMY trial.
von Lewinski D; Kolesnik E; Tripolt NJ; Pferschy PN; Benedikt M; Wallner M; Alber H; Berger R; Lichtenauer M; Saely CH; Moertl D; Auersperg P; Reiter C; Rieder T; Siller-Matula JM; Gager GM; Hasun M; Weidinger F; Pieber TR; Zechner PM; Herrmann M; Zirlik A; Holman RR; Oulhaj A; Sourij H
Eur Heart J; 2022 Nov; 43(41):4421-4432. PubMed ID: 36036746
[TBL] [Abstract][Full Text] [Related]
10. EMMY: The continued expansion of clinical applications of SGLT2 inhibitors.
Kotit S
Glob Cardiol Sci Pract; 2023 Jan; 2023(1):e202305. PubMed ID: 36890845
[No Abstract] [Full Text] [Related]
11. Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus.
Mozawa K; Kubota Y; Hoshika Y; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Maruyama M; Tanabe J; Shimizu W
ESC Heart Fail; 2021 Oct; 8(5):4161-4173. PubMed ID: 34235875
[TBL] [Abstract][Full Text] [Related]
12. Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial.
Aziz F; Tripolt NJ; Pferschy PN; Kolesnik E; Mangge H; Curcic P; Hermann M; Meinitzer A; von Lewinski D; Sourij H;
Cardiovasc Diabetol; 2023 Jul; 22(1):184. PubMed ID: 37475009
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
[TBL] [Abstract][Full Text] [Related]
14. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335
[TBL] [Abstract][Full Text] [Related]
15. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
Cardiovasc Diabetol; 2021 Jun; 20(1):105. PubMed ID: 34183012
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
17. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Fosbøl EL; Bruun NE; Brønd JC; Forman JL; Videbæk L; Møller JE; Schou M
Am Heart J; 2020 Oct; 228():47-56. PubMed ID: 32798787
[TBL] [Abstract][Full Text] [Related]
18. Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post-hoc analysis of the EMMY trial.
Sourij C; Oulhaj A; Aziz F; Tripolt NJ; Aberer F; Pferschy PN; Postula M; Drexel H; Benedikt M; Kolesnik E; Pieber TR; Bugger H; von Lewinski D; Sourij H
Diabetes Obes Metab; 2024 May; 26(5):1971-1975. PubMed ID: 38287198
[No Abstract] [Full Text] [Related]
19. Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin.
Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
Cardiovasc Diabetol; 2021 Jul; 20(1):160. PubMed ID: 34332584
[TBL] [Abstract][Full Text] [Related]
20. Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus.
Hoshika Y; Kubota Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Maruyama M; Tanabe J; Shimizu W
Diabetes Ther; 2021 Aug; 12(8):2241-2248. PubMed ID: 34236577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
